BioPharma Dive July 18, 2024
The offering comes days after the publication of a paper showing what analysts said was early proof that “off-the-shelf” cell therapies can treat inflammatory diseases.
Dive Brief:
- Artiva Biotherapeutics on Thursday raised $167 million in an initial public offering centered around the promise of donor-derived cell therapies for autoimmune diseases.
- Artiva sold 13.92 million shares at $12 apiece, securing more money than it expected but at a lower per-share price than it had outlined earlier this week. The bulk of the proceeds will fund a treatment made from “natural killer,” or NK, cells and that is currently in early-stage testing in lupus and other inflammatory conditions. Shares will begin trading on the Nasdaq stock exchange Friday under the ticker...
Today's Sponsors
Today's Sponsor